CymaBay Therapeutics ROE 2013-2018 | CBAY

Current and historical return on equity (ROE) values for CymaBay Therapeutics (CBAY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. CymaBay Therapeutics ROE for the three months ending December 31, 2018 was -37.69%.
CymaBay Therapeutics ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-12-31 $-0.07B $0.17B -37.97%
2018-09-30 $-0.06B $0.19B -34.50%
2018-06-30 $-0.05B $0.20B -32.93%
2018-03-31 $-0.04B $0.21B -40.41%
2017-12-31 $-0.03B $0.09B -59.02%
2017-09-30 $-0.03B $0.09B -113.73%
2017-06-30 $-0.03B $0.00B -432.00%
2017-03-31 $-0.03B $0.01B -263.16%
2016-12-31 $-0.03B $0.00B -211.76%
2016-09-30 $-0.03B $0.01B -138.67%
2016-06-30 $-0.03B $0.02B -106.12%
2016-03-31 $-0.02B $0.02B -79.21%
2015-12-31 $-0.02B $0.03B -61.86%
2015-09-30 $-0.02B $0.03B -106.02%
2015-06-30 $-0.02B $0.02B -115.79%
2015-03-31 $-0.02B $0.02B -145.45%
2014-12-31 $-0.03B $0.01B -216.95%
2014-09-30 $0.19B $0.03B 1206.25%
2014-06-30 $0.24B $0.01B 1668.97%
2014-03-31 $0.24B $0.01B 1920.00%
2013-12-31 $0.24B $0.02B 2502.56%
2013-09-30 $0.03B $0.02B 640.00%
2013-06-30 $-0.02B $0.00B inf%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.794B $0.010B
CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based in Newark, California.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $50.172B 9.03
Teva Pharmaceutical Industries (TEVA) Israel $16.921B 5.84
Mylan (MYL) United Kingdom $14.539B 6.15
Bausch Health Cos (BHC) Canada $8.584B 6.10
Dr Reddy's Laboratories (RDY) India $6.489B 25.88
Supernus Pharmaceuticals (SUPN) United States $2.008B 18.63
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.896B 3.08
Homology Medicines (FIXX) United States $1.048B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.953B 88.57
Voyager Therapeutics (VYGR) United States $0.616B 0.00
Assembly Biosciences (ASMB) United States $0.502B 0.00
Akorn (AKRX) United States $0.432B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.389B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.215B 0.00
Sol-Gel Technologies (SLGL) Israel $0.132B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.102B 0.00
Acasti Pharma (ACST) Canada $0.083B 0.00
Teligent (TLGT) United States $0.070B 0.00
Agile Therapeutics (AGRX) United States $0.069B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.064B 0.00
Evoke Pharma (EVOK) United States $0.025B 0.00
Aevi Genomic Medicine (GNMX) United States $0.015B 0.00
China Pharma Holdings (CPHI) China $0.014B 0.00